However, it is still not clear whether ERα-ΔNp63-integrin β4 signaling results in tamoxifen-resistance in ERα-positive breast cancer or how integrinβ4 downstream signaling pathways interact during breast cancer progression. This evidence concerns the gene ESR1 and breast carcinoma.